INHIBITORY EFFECTS OF SURAMIN ON A HUMAN RENAL-CELL CARCINOMA LINE, CAUSING NEPHROGENIC HEPATIC-DYSFUNCTION

被引:17
作者
CHANG, SY [1 ]
YU, DS [1 ]
SHERWOOD, ER [1 ]
KOZLOWSKI, JM [1 ]
LEE, C [1 ]
机构
[1] NORTHWESTERN UNIV,SCH MED,DEPT UROL,GENITOURINARY ONCOL PROGRAM,CHICAGO,IL 60611
关键词
KIDNEY NEOPLASMS; SURAMIN; INTERFERON; TUMOR NECROSIS FACTOR;
D O I
10.1016/S0022-5347(17)37505-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A sarcomatoid renal cell carcinoma has been isolated from a patient with Stauffer's syndrome. The tumor, designated BA1119, has been established in tissue culture over 80 passages. Subcutaneous deposition of BA1119 in athymic mice induced splenomegaly and hepatic dysfunction which became fatal within four weeks without metastasis. Suramin is a synthetic polyanionic compound which is capable of altering the function of a number of biologic systems and inhibiting the activity of a variety of protein and growth factors. In this study we attempted to study the effect of suramin on growth of BA1119 in culture and in nude mice. Suramin, at 300-mu-g./ml., had a profound inhibitory effect on cell growth during a six-day culture period. Suramin given i.p. weekly to nude mice at clinically relevant doses (200 mg./kg.) caused significant shrinkage of subcapsular tumor deposits. Splenic hypertrophy secondary to BA1119-induced Stauffer's syndrome was inhibited by suramin. Synergistic effect with enhanced cytotoxicity on BA1119 cells was observed when suramin (100-mu-g./ml.) was used in combination with lymphokines, such as gamma interferon (500 units/ml.) and alpha tumor necrosis factor (300 ng./ml.). These results may suggest a therapeutic efficacy of suramin in renal cell carcinoma patients with Stauffer's syndrome.
引用
收藏
页码:1147 / 1150
页数:4
相关论文
共 31 条
[1]  
ALEXANDER RB, 1987, CANCER RES, V47, P2403
[2]   THE INHIBITION OF HUMAN ADRENAL STEROIDOGENIC ENZYME-ACTIVITIES BY SURAMIN [J].
ASHBY, H ;
DIMATTINA, M ;
LINEHAN, WM ;
ROBERTSON, CN ;
QUEENAN, JT ;
ALBERTSON, BD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (02) :505-508
[3]  
BRANDELY M, 1985, CELL IMMUNOL, V93, P292
[4]  
BRODER S, 1985, LANCET, V2, P627
[5]   SURAMIN THERAPY IN AIDS AND RELATED DISORDERS - REPORT OF THE UNITED-STATES-SURAMIN-WORKING-GROUP [J].
CHESON, BD ;
LEVINE, AM ;
MILDVAN, D ;
KAPLAN, LD ;
WOLFE, P ;
RIOS, A ;
GROOPMAN, JE ;
GILL, P ;
VOLBERDING, PA ;
POIESZ, BJ ;
GOTTLIEB, MS ;
HOLDEN, H ;
VOLSKY, DJ ;
SILVER, SS ;
HAWKINS, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (10) :1347-1351
[6]   SURAMIN INHIBITION OF GROWTH-FACTOR RECEPTOR-BINDING AND MITOGENICITY IN AKR-2B CELLS [J].
COFFEY, RJ ;
LEOF, EB ;
SHIPLEY, GD ;
MOSES, HL .
JOURNAL OF CELLULAR PHYSIOLOGY, 1987, 132 (01) :143-148
[7]  
COLLINS JM, 1986, J CLIN PHARMACOL, V26, P22
[8]   EXPERIMENTAL ANIMAL-MODEL FOR MUCOPOLYSACCHARIDOSIS - SURAMIN-INDUCED GLYCOSAMINOGLYCAN AND SPHINGOLIPID ACCUMULATION IN THE RAT [J].
CONSTANTOPOULOS, G ;
REES, S ;
CRAGG, BG ;
BARRANGER, JA ;
BRADY, RO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (06) :3700-3704
[9]  
DECLERQ E, 1974, CANCER LETT, V8, P9
[10]  
EISEN V, 1973, BRIT J PHARMACOL, V49, P678, DOI 10.1111/j.1476-5381.1973.tb08544.x